Clinical Trials Webinar Announcement
Following the recent announcement about the GTX-102 trial in the UK, MDUK Oxford Neuromuscular Center has kindly arranged a webinar for the Angelman Syndrome community. Professor Laurent Servais, Dr Dora Markati, our own Julien de Bournet and AngelmanUK’s Dr Katie Cunnea will not only cover the upcoming trial, but also other pre-clinical and clinical developments, and the Natural History Study in Oxford.
Dear Angelman-Syndrome Community,
You may have heard that a new Phase 1 trial into Angelman-Syndrome has been recently approved by the MHRA and will soon include a very limited number of patients in the UK.
With the participation of Angelman UK and FAST UK, two charities firmly committed to supporting the Angelman-Syndrome community, we strongly believe this is a significant step to progress Angelman-Syndrome research. In this context, we propose to host on July 1st 8 PM UK time a webinar to inform you transparently about this trial and the developments that are occurring.
We appreciate that any choice of time could be difficult for families to accommodate, and we will therefore record the webinar and make the link available for the community.
The program will be as follows:
- Welcome, introduction and objective: Prof. Laurent Servais (University of Oxford)
- How can a drug work to treat Angelman Syndrome?: Dr Katie Cunnea (Angelman UK)
- Current preclinical and clinical developments in Angelman Syndrome: Dr Theodora Markati (University of Oxford)
- The natural history study in Oxford – our readiness for clinical trials: Julien de Bournet (FAST UK)
- GeneTX Phase 1 Trial: Prof. Laurent Servais
- Q & A
The aim of this webinar is to transparently provide the Angelman-Syndrome community with the general information regarding trials and developments. We will not, of course, discuss individual patients or inclusion, which must be discussed privately with the investigators.
We look forward to speaking with you.